Amag Pharmaceuticals downgraded to Underweight from Neutral at Piper Jaffray
October 30, 2019 at 10:30 AM EDT
Piper Jaffray analyst Christoper Raymond downgraded Amag Pharmaceuticals to Underweight from Neutral with a price target of $6, down from $9.
